Who are doxepin solution's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Anafranil, Amoxan, Surmontil, Zonalon, Triptil, Aventyl.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/doxepin-solution.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

doxepin solution — Competitive Intelligence Brief

doxepin solution (doxepin solution) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: tricyclic antidepressant. Area: Psychiatry.

phase 3 tricyclic antidepressant Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

doxepin solution (doxepin solution) — Nanfang Hospital, Southern Medical University. Doxepin solution is a tricyclic antidepressant that works by inhibiting the reuptake of serotonin and norepinephrine.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
doxepin solution TARGET	doxepin solution	Nanfang Hospital, Southern Medical University	phase 3	tricyclic antidepressant
Anafranil	CLOMIPRAMINE	Specgx Llc	marketed	Tricyclic Antidepressant	Sodium-dependent serotonin transporter	1989-01-01
Amoxan	AMOXAPINE	Pfizer	marketed	Tricyclic Antidepressant [EPC]	5-hydroxytryptamine receptor 2A	1980-01-01
Surmontil	TRIMIPRAMINE	Teva Womens	marketed	Tricyclic Antidepressant	Histamine H1 receptor	1979-01-01
Zonalon	DOXEPIN		marketed	Tricyclic Antidepressant	Histamine H1 receptor	1969-01-01
Triptil	PROTRIPTYLINE		marketed	Tricyclic Antidepressant	Adenosine receptor A3	1967-01-01
Aventyl	NORTRIPTYLINE		marketed	Tricyclic Antidepressant	Sodium-dependent noradrenaline transporter	1964-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (tricyclic antidepressant class)

Nanfang Hospital, Southern Medical University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). doxepin solution — Competitive Intelligence Brief. https://druglandscape.com/ci/doxepin-solution. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab